Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

83.0K
Overview
83.0K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

2.5K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.5K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

351
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
351
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

383
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
383
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

1.9K
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
1.9K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

372
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
372

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical characteristics and prognostic value of pre-retreatment plasma epstein-barr virus DNA in locoregional recurrent nasopharyngeal carcinoma.

Cancer medicine·2019
Same author

Correlation of sleep microstructure with daytime sleepiness and cognitive function in young and middle-aged adults with obstructive sleep apnea syndrome.

European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery·2019
Same author

Orbital-flop Induced Magnetoresistance Anisotropy in Rare Earth Monopnictide CeSb.

Nature communications·2019
Same author

Author Correction: Identification of TC2N as a novel promising suppressor of PI3K-AKT signaling in breast cancer.

Cell death & disease·2019
Same author

A hybrid gene selection method based on gene scoring strategy and improved particle swarm optimization.

BMC bioinformatics·2019
Same author

TL1A modulates the severity of colitis by promoting Th9 differentiation and IL-9 secretion.

Life sciences·2019

Related Experiment Video

Updated: Dec 22, 2025

Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation
11:49

Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation

Published on: May 2, 2013

16.5K

Triptolide Attenuates Transplant Vasculopathy Through Multiple Pathways.

Zihuan Luo1, Tao Liao1, Yannan Zhang1

  • 1Organ Transplantation Research Institute, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.

Frontiers in Immunology
|May 7, 2020
PubMed
Summary
This summary is machine-generated.

Triptolide effectively inhibits transplant vasculopathy (TV), a major cause of organ transplant rejection. This compound reduces immune cell infiltration and inflammatory factors, offering a potential new treatment for TV.

Keywords:
IFN-γdonor-specific antibodiestransplant vasculopathytriptolidevascular smooth muscle cells

More Related Videos

Mouse Model of Alloimmune-induced Vascular Rejection and Transplant Arteriosclerosis
07:05

Mouse Model of Alloimmune-induced Vascular Rejection and Transplant Arteriosclerosis

Published on: May 17, 2015

8.8K
Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

17.3K

Related Experiment Videos

Last Updated: Dec 22, 2025

Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation
11:49

Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation

Published on: May 2, 2013

16.5K
Mouse Model of Alloimmune-induced Vascular Rejection and Transplant Arteriosclerosis
07:05

Mouse Model of Alloimmune-induced Vascular Rejection and Transplant Arteriosclerosis

Published on: May 17, 2015

8.8K
Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

17.3K

Area of Science:

  • Immunology
  • Transplantation Biology
  • Pharmacology

Background:

  • Transplant vasculopathy (TV) is a primary cause of chronic allograft rejection and subsequent organ loss.
  • Current therapeutic strategies for TV are limited due to its complex, multifactorial pathogenesis.

Purpose of the Study:

  • To investigate the efficacy of triptolide, a compound with known immunosuppressive properties, in preventing or treating transplant vasculopathy.
  • To elucidate the molecular mechanisms by which triptolide impacts TV development in a murine model.

Main Methods:

  • Utilized a murine aortic transplant model, comparing triptolide-treated and untreated groups.
  • Assessed histological changes, immune cell infiltration (T lymphocytes, macrophages, B lymphocytes), and levels of inflammatory and fibrotic factors.
  • Evaluated the effects of triptolide on vascular smooth muscle cell (VSMC) viability, apoptosis, and migration in vitro.

Main Results:

  • Triptolide significantly reduced intimal thickening in allografts.
  • Triptolide decreased infiltration of T lymphocytes and macrophages, and lowered pro-inflammatory (TNF-α, IL-2, IL-6) and pro-fibrotic (TGF-β, α-SMA, MMP-9) factors.
  • Triptolide reduced IFN-γ-producing T cells, IFN-γ, and its inducers (CXCL9, CXCL10), as well as B cells, plasma cells, and donor-specific antibodies (DSAs).
  • Triptolide inhibited VSMC viability, promoted VSMC apoptosis, and suppressed VSMC migration.

Conclusions:

  • Triptolide demonstrates significant efficacy in inhibiting transplant vasculopathy development.
  • Triptolide acts through multiple pathways, including reducing immune cell infiltration, inflammation, fibrosis, and impacting VSMC behavior.
  • These findings support triptolide as a potential therapeutic agent for preventing TV and improving long-term transplant outcomes.